Overview

The primary objective of this trial is to investigate safety and tolerability of BI 1356225 in male and female patients with overweight and obesity following oral administration of multiple rising doses per day over 28 days. Secondary objectives are the exploration of pharmacokinetics (PK) of BI 1356225 after multiple oral dosing. Additionally, the relative bioavailability (BA) of midazolam and celecoxib in the presence and absence of BI 1356225 will be evaluated

Eligibility

Inclusion criteria

• Male and female patients, age 18 and < 70
• Body Mass Index 27 kg/m2 and < 40 kg/m2 at screening
• Stable body weight (defined as no more than 5% change) within 3 months prior to screening
• further inclusion criteria apply

Exclusion criteria

• Females of childbearing potential
• Clinically relevant concomitant disease per investigator judgment
• Any condition or disease requiring permanent pharmacotherapy during the trial
• Any history of lifetime suicidal behaviour and any suicidal ideation of type 2 - 5 in the Columbia-Suicide Severity Rating Scale (C-SSRS) in the past 12 months
• further exclusion criteria apply